KALA BIO, INC. Payments to Acquire Short-term Investments
KALA BIO, INC. (KALA) reported Payments to Acquire Short-term Investments of $7.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-05-15
- KALA BIO, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $7.00M.
- KALA BIO, INC. payments to acquire short-term investments for the quarter ending 2023-12-31 was $0.00.
- KALA BIO, INC. payments to acquire short-term investments for the quarter ending 2023-09-30 was $0.00.
- KALA BIO, INC. payments to acquire short-term investments for the quarter ending 2022-12-31 was $0.00.
- KALA BIO, INC. payments to acquire short-term investments for fiscal 2023 was $9.87M, a 97.64% increase from fiscal 2022.
- KALA BIO, INC. payments to acquire short-term investments for fiscal 2022 was $4.99M.
- KALA BIO, INC. payments to acquire short-term investments for fiscal 2020 was $113.59M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-15 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $9.87M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $9.87M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $9.87M 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $4.99M 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $4.99M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $4.99M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $4.99M 10-Q · filed 2023-05-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $57.06M derived: sum of 2 quarters · filed 2022-03-29 | $113.59M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $57.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $113.59M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $56.53M 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |